

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF  
FOSTER ET AL.

Art Unit: 1617  
Examiner: Javanmard,  
Sahar

INTERNATIONAL APPLICATION NO: PCT/EP2003/010579

FILED: 23 SEPTEMBER 2003

U.S. APPLICATION NO: 10/528,688

35 USC §371 DATE: 17 MAY 2005

FOR: SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS IN THE  
TREATMENT OF DEMYELINATING DISORDERS

**MS: Amendment**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is supplemental to the Information Disclosure Statement filed September 19, 2006. Since it is being filed in accordance with 37 C.F.R. §1.97(c), a letter for payment of fee set forth in 37 C.F.R. §1.17(p) is enclosed.


In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

Novartis Pharmaceuticals Corp.  
Patents Pharma  
One Health Plaza, Building 104  
East Hanover, NJ 07936-1080  
(862) 778-9273

  
Cozette McAvoy  
Attorney for Applicants  
Reg. No. 60,457

Date: *3rd October 2008*